Analysts Offer Predictions for CMPS Q1 Earnings

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Stock analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Compass Pathways in a report released on Wednesday, March 25th. HC Wainwright analyst P. Trucchio expects that the company will earn ($0.42) per share for the quarter. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($2.33) per share. HC Wainwright also issued estimates for Compass Pathways’ Q2 2027 earnings at ($0.27) EPS, Q3 2027 earnings at ($0.18) EPS and Q4 2027 earnings at ($0.08) EPS.

CMPS has been the subject of several other research reports. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. Canaccord Genuity Group decreased their price target on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating for the company in a report on Thursday. Royal Bank Of Canada upped their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday, February 18th. Finally, Morgan Stanley dropped their price objective on Compass Pathways from $18.00 to $16.00 and set an “overweight” rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Compass Pathways currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.63.

Compass Pathways Stock Performance

Shares of NASDAQ:CMPS opened at $5.37 on Thursday. The firm’s 50 day simple moving average is $6.66 and its 200 day simple moving average is $6.30. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.90. The company has a market capitalization of $515.63 million, a price-to-earnings ratio of -1.74 and a beta of 1.90. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.77 and a quick ratio of 1.23.

Compass Pathways (NASDAQ:CMPS) last posted its earnings results on Tuesday, March 24th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.59).

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Persistent Asset Partners Ltd bought a new stake in Compass Pathways in the 4th quarter valued at $38,000. Advisory Services Network LLC acquired a new stake in shares of Compass Pathways in the 3rd quarter valued at about $41,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Compass Pathways in the fourth quarter valued at about $47,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Compass Pathways by 46.7% in the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after purchasing an additional 5,817 shares in the last quarter. Finally, BIT Capital GmbH acquired a new position in shares of Compass Pathways during the third quarter worth about $54,000. Institutional investors own 46.19% of the company’s stock.

Trending Headlines about Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating with a very high $70 price target, signaling a strong long‑term bullish case and large implied upside versus the current share price. (This supports investor optimism even as near‑term forecasts were adjusted.)
• Neutral Sentiment: Upcoming FDA review meeting for COMP360 is a potential binary catalyst — outcomes or guidance from that meeting could swing sentiment materially in either direction. Compass Pathways (CMPS): What will come out of FDA review meeting for depression drug candidate COMP360?
• Neutral Sentiment: Canaccord cut its price target from $20 to $18 but kept a “Buy” rating — a modest downgrade that still implies significant upside from current levels. Canaccord target cut report
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast to ($1.66) from ($1.36) and cut FY2027 to ($0.96) (previously $0.72), and issued lower quarterly EPS estimates across 2026–2027 — firms’ reduced profit outlook increases short‑term pressure on the share price.
• Negative Sentiment: Morgan Stanley trimmed its price target to $16, which reduces near‑term upside and may prompt short‑term selling. Morgan Stanley Lowers Compass Pathways (NASDAQ:CMPS) Price Target to $16.00
• Negative Sentiment: Recent earnings (reported 3/24) missed estimates (EPS -$1.00 vs. consensus -$0.41), reinforcing concerns on near‑term profitability and contributing to downward pressure on the stock.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.